Results 151 to 160 of about 432,090 (383)

Comparative Efficacy and Safety of Anakinra and Canakinumab in Patients With VEXAS Syndrome: An International Multicenter Study

open access: yesArthritis &Rheumatology, EarlyView.
Objective The aim of this study was to compare differences in clinical response, drug survival, and adverse event rates between anakinra and canakinumab in VEXAS (vacuoles, E1 enzyme, X‐linked, autoinflammatory, somatic) syndrome. Methods This multicenter international study includes patients with VEXAS from France, Israel, and Italy treated with ...
Tali Eviatar   +35 more
wiley   +1 more source

Nonalcoholic Fatty Liver Disease and Thrombocytopenia III: Its Association With Insulin Resistance

open access: yesClinical and Applied Thrombosis/Hemostasis, 2019
Thrombocytopenia (less than 100 × 10 9 /L platelets) presents in around one quarter of patients with nonalcoholic fatty liver disease (NAFLD), the hepatic component of insulin resistance (IR).
Miguel Antonio López-Trujillo Bsc   +9 more
doaj   +1 more source

Understanding and Managing Thrombocytopenia in Pregnancy: A Case Series [PDF]

open access: yesJournal of Clinical and Diagnostic Research
Thrombocytopenia, defined as a platelet count of less than 1.5 L/mm3, is a common haematological disorder encountered during pregnancy. It can arise from a variety of causes, including immune-mediated destruction, gestational thrombocytopenia, and ...
Akshaya Radhakrishnan   +3 more
doaj   +1 more source

Human Inborn Errors of Immunity: 2019 Update of the IUIS Phenotypical Classification. [PDF]

open access: yes, 2020
Since 2013, the International Union of Immunological Societies (IUIS) expert committee (EC) on Inborn Errors of Immunity (IEI) has published an updated phenotypic classification of IEI, which accompanies and complements their genotypic classification ...
Ailal, Fatima   +18 more
core  

Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination

open access: yesNew England Journal of Medicine, 2021
Kate-Lynn E. Muir   +3 more
semanticscholar   +1 more source

A Randomized, Placebo‐Controlled Trial of Hydroxychloroquine in Incomplete Lupus

open access: yesArthritis &Rheumatology, EarlyView.
Objective Patients with features of systemic lupus erythematosus (SLE) who do not fulfill classification criteria can be designated as incomplete lupus erythematosus (ILE). This condition includes individuals with a high risk of progression to SLE. Treatment of ILE may reduce symptoms, severity, and incidence of SLE.
Nancy J. Olsen   +14 more
wiley   +1 more source

Home - About - Disclaimer - Privacy